In addition, the low expression of TXNIP had better OS in AML patients (1-year OS: TXNIPlow vs. TXNIPhigh, 77% vs 45%, HR = 0.19, 95%CI: 0.05 to 0.81, P = 0.025, Figure 4B). Here, TXNIP is linked to acute myeloid leukemia.